Welcome To The Resverlogix HUB On AGORACOM

**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Trial and a Phase 2 Kidney Trial is Planned for 2017**



Tetra Bio-Pharma Reports Approval by Health Canada of its Phase 1 Trial of dried Cannabis

  • Health Canada approved phase I clinical study of smoked cannabis

We are very pleased to announce the authorization of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies, said Dr. Chamberland, Chief Science Officer.

Tbp large

Hub On AGORACOM / Read Release


Message: A few comments

Hey tada, I guess we shall see whether or not AZN and PFE renew merger talks. Given that AZN's pipeline is one of the weakest in pharma yet they had no presence at JP Morgan this week for the first time in a long time if ever, makes me wonder. But that is just me.  


WRT a CVR, I agree that is the most likely scenario especially if someone steps up early to buy just Apabetalone.  Buying the whole company however probably might make more sense to a purchaser given the $250mm in tax credits, a nice offset to upfront money, and a growing pool of potentially valuable IP.  If a CVR is done after a successful read out for BetOnMace (in mid 2018 not 2019) I strongly doubt that a few hundred million dollars upfront would even come close to being enough money to get a deal done. It might be enough if someone steps up before BetOnMace is complete.  Jmo

New Message
Please login to post a reply